Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 542

1.

cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.

Odia Y, Orr BA, Bell WR, Eberhart CG, Rodriguez FJ.

J Neurooncol. 2013 Nov;115(2):249-59. doi: 10.1007/s11060-013-1221-4. Epub 2013 Aug 11.

2.

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D.

J Neurooncol. 2011 Nov;105(2):345-57. doi: 10.1007/s11060-011-0596-3. Epub 2011 Jun 4.

PMID:
21643842
3.

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.

Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A.

J Neurooncol. 2012 Jul;108(3):361-73. doi: 10.1007/s11060-012-0837-0. Epub 2012 Mar 7.

PMID:
22396072
4.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

5.

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.

Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z. Epub 2010 Nov 19.

PMID:
21088844
6.

Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

Figarella-Branger D, Bouvier C, de Paula AM, Mokhtari K, Colin C, Loundou A, Chinot O, Metellus P.

J Neurooncol. 2012 Nov;110(2):205-13. doi: 10.1007/s11060-012-0953-x. Epub 2012 Aug 14.

PMID:
22890969
7.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

8.

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network.

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.

9.

KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.

Gousias K, Niehusmann P, Gielen G, Simon M, Boström J.

J Clin Neurosci. 2014 Oct;21(10):1719-24. doi: 10.1016/j.jocn.2014.01.011. Epub 2014 Jun 11.

PMID:
24929863
10.

IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.

Chen N, Yu T, Gong J, Nie L, Chen X, Zhang M, Xu M, Tan J, Su Z, Zhong J, Zhou Q.

Pathology. 2016 Dec;48(7):675-683. doi: 10.1016/j.pathol.2016.07.010. Epub 2016 Oct 22.

PMID:
27780605
11.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3. Epub 2014 Nov 27.

12.

[Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].

Pan Y, Qi XL, Wang LM, Dong RF, Zhang M, Zheng DF, Chang Q, Zhong YF.

Zhonghua Bing Li Xue Za Zhi. 2013 May;42(5):292-8. doi: 10.3760/cma.j.issn.0529-5807.2013.05.002. Chinese.

PMID:
24004584
13.

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK, Jha P.

Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015. Epub 2013 Mar 13.

14.

Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.

Ogura R, Tsukamoto Y, Natsumeda M, Isogawa M, Aoki H, Kobayashi T, Yoshida S, Okamoto K, Takahashi H, Fujii Y, Kakita A.

Neuropathology. 2015 Aug;35(4):324-35. doi: 10.1111/neup.12196. Epub 2015 May 6.

PMID:
25950388
15.

Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F.

J Neurooncol. 2010 Sep;99(2):209-15. doi: 10.1007/s11060-010-0129-5. Epub 2010 Feb 21.

PMID:
20174854
16.

Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.

Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network.

Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31.

PMID:
25407774
17.

Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D.

Neuro Oncol. 2013 Jun;15(6):682-90. doi: 10.1093/neuonc/not006. Epub 2013 Feb 14.

18.

Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival.

Korkolopoulou P, Levidou G, El-Habr EA, Adamopoulos C, Fragkou P, Boviatsis E, Themistocleous MS, Petraki K, Vrettakos G, Sakalidou M, Samaras V, Zisakis A, Saetta A, Chatziandreou I, Patsouris E, Piperi C.

Br J Cancer. 2013 May 28;108(10):2142-52. doi: 10.1038/bjc.2013.176. Epub 2013 Apr 25.

19.

Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.

Kanamori M, Higa T, Sonoda Y, Murakami S, Dodo M, Kitamura H, Taguchi K, Shibata T, Watanabe M, Suzuki H, Shibahara I, Saito R, Yamashita Y, Kumabe T, Yamamoto M, Motohashi H, Tominaga T.

Neuro Oncol. 2015 Apr;17(4):555-65. doi: 10.1093/neuonc/nou282. Epub 2014 Oct 10.

Supplemental Content

Support Center